More about

Atezolizumab

News
September 07, 2022
2 min watch
Save

VIDEO: World Conference on Lung Cancer offers ‘impactful treatment-related research’

VIDEO: World Conference on Lung Cancer offers ‘impactful treatment-related research’

In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.

News
August 24, 2022
4 min watch
Save

VIDEO: Adjuvant, neoadjuvant therapy in non-small cell lung cancer is ‘here to stay’

VIDEO: Adjuvant, neoadjuvant therapy in non-small cell lung cancer is ‘here to stay’

Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2

News
August 23, 2022
2 min watch
Save

VIDEO: Expert highlights data on treatments for KRAS G12C non-small cell lung cancer

VIDEO: Expert highlights data on treatments for KRAS G12C non-small cell lung cancer

In this video, Jia Luo, MD, discusses two presentations from International Association for the Study of Lung Cancer World Conference on Lung Cancer investigating treatments for KRAS G12C lung cancer.

News
August 03, 2022
1 min read
Save

Atezolizumab plus chemotherapy regimen safe, effective for squamous cell anal carcinoma

Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.

News
July 31, 2022
1 min read
Save

World Lung Cancer Day: New therapies, novel combinations confer benefit

World Lung Cancer Day: New therapies, novel combinations confer benefit

World Lung Cancer Day will be held Aug. 1.

News
July 18, 2022
1 min read
Save

Atezolizumab plus FLOT regimen beneficial for resectable esophagogastric adenocarcinoma

The effects of atezolizumab combined with a chemotherapy regimen were beneficial in terms of pathologic outcome compared with the chemotherapy regimen alone for patients with resectable esophagogastric adenocarcinoma.

News
July 06, 2022
2 min watch
Save

VIDEO: COMMIT study accruing first-line patients with MSI-high colorectal cancer

VIDEO: COMMIT study accruing first-line patients with MSI-high colorectal cancer

In this video, Howard S. Hochester, MD, discusses the COMMIT study comparing the anti-PD1 drug atezolizumab with atezolizumab combined with FOLFOX chemotherapy presented as part of a poster session at ASCO Annual Meeting.

News
June 25, 2022
2 min read
Save

Primary trial results show no benefit from anti-TIGIT addition in small cell lung cancer

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.

News
June 22, 2022
3 min read
Save

Cabozantinib plus atezolizumab shows potential in advanced urothelial carcinoma

CHICAGO — Cabozantinib plus atezolizumab showed encouraging clinical activity in patients with inoperable locally advanced or metastatic urothelial carcinoma, according to data from the COSMIC-021 study.

News
June 08, 2022
11 min listen
Save

Top Headlines in Lung Cancer: AYA secondary cancer risk; phase 3 trial misses co-primary endpoint; and more

Top Headlines in Lung Cancer: AYA secondary cancer risk; phase 3 trial misses co-primary endpoint; and more

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.

View more